WALTHAM, Mass., July 14 Decision Resources, one of theworld's leading research and advisory firms focusing on pharmaceutical andhealthcare issues, finds that in 2007, the United States market for thetreatment of pulmonary symptoms of cystic fibrosis reached $397 million,reflecting primarily sales of Genentech/Roche's Pulmozyme and Novartis'santibiotic Tobi. Sales of these agents have helped the market grow at morethan 15 percent annually since 2000. That growth however, may slow as sales ofthese agents level off or until a new treatment option emerges.
The new Spectrum Orphan Disease Series report entitled Cystic Fibrosis:Will New Agents Emerge as First-Line Therapies? also finds that cysticfibrosis only affects 28,500 people living in the United States. However,despite a relatively static incidence rate, the prevalence of this diseasewill rise as improved treatments increase patient longevity. Although currenttreatment options have resulted in reduced mortality in cystic fibrosispatients, there is still a need for more efficacious or convenient therapies.
"The advent of therapies that address the root cause of cystic fibrosis --faulty chloride transport -- will drive a radical change in how the disease istreated and, consequentially, the market," said Jennifer Moniz Carpenter,analyst at Decision Resources. "As these new therapies -- the closestresearchers have come to a cure -- are approved and adopted into treatmentregimens, the current therapies that address symptoms of the disease willlikely see a drop in market share. However, the overall effect on the marketis likely to be a positive one, as any agent that can effectively restorechloride transport will achieve strong uptake and can demand premium pricing."
About Decision Resources' Spectrum Orphan Disease Series
Orphan drug status can offer companies a number of unique advantages fortheir agents, particularly as competition increases in larger disease statesand the hurdles to gaining regulatory approval increase. Decision Resources'Spectrum Orphan Disease Series provides critical market information fordiseases with smaller patient populations, including disease prevalence,profiles of marketed and emerging agents and insight into the prescribingchoices of disease specialists. These reports will help you to maximize thepotential of your agents in these challenging markets, including insights intothe regulatory benefits available and the potential for partnership withcharitable organizations.
The reports can be purchased by contacting Decision Resources. Members ofthe media may request an interview with an analyst.
About Decision Resources
Decision Resources (http://www.decisionresources.com) is a world leader inmarket research publications, advisory services and consulting designed tohelp clients shape strategy, allocate resources and master their chosenmarkets. Decision Resources is a Decision Resources, Inc. company.
All company, brand, or product names contained in this document may betrademarks or registered trademarks of their respective holders.Select titles from the Spectrum Orphan Disease Series include: -- Amyotrophic Lateral Sclerosis: Strategies for Drug Developers -- Cystic Fibrosis: Will New Agents Emerge as First-Line Therapies? -- Glaucoma: Can Orphan-Drug Status Offer an Entry into a Mature Market?
SOURCE Decision Resources